Skip to content
Food

PepsiCo Appoints Johnson & Johnson CEO Joaquin Duato to Board

By Sarah Chen
2 min read
pepsi
pepsi
In this article (9)

PepsiCo has appointed Johnson & Johnson chairman and CEO Joaquin Duato to its board of directors and as an independent member of its audit committee, effective in December.

Duato has spent more than three decades at Johnson & Johnson, stepping into the role of chief executive in 2022 before adding the chairmanship in 2023.

Director Compensation and Audit Role

Under PepsiCo’s non-employee director compensation program, Duato receives an initial grant of 1,000 shares of common stock upon taking his seat. The company will also award him a prorated annual equity package in phantom stock units valued at $166,667, calculated by dividing that sum by the stock’s closing price on December 1, 2026.

Each phantom unit represents the economic equivalent of one share of common stock. Duato will also receive cash compensation for his board service, starting with a semi-annual retainer payment of $60,000 scheduled for distribution in June 2027.

Three Decades of Operational Leadership

Duato, 64, has spent his career navigating large-scale distribution, consumer health manufacturing and international supply chains. He joined Johnson & Johnson in 1989 and held multiple executive posts before taking the chief executive role in 2022 and adding the chairmanship in 2023.

His previous responsibilities included serving as vice chairman of the executive committee and worldwide chairman of pharmaceuticals. Across those roles, Duato directed commercial portfolios that spanned consumer health, medical technologies and enterprise software deployment.

Governance Focus for Packaged Goods

Consumer goods manufacturers face tighter scrutiny over ingredient sourcing, functional nutrition claims and international compliance standards. Adding seasoned pharmaceutical leadership gives PepsiCo direct access to enterprise-level regulatory risk management as packaged food lines shift toward health-focused formulations.

RetailNews Asia views the addition of dual-sector executive experience as a defensive step for consumer packaged goods boards. Large food companies are managing stricter packaging directives and retail price pushback across emerging markets, where audit committees must balance heavy capital spending on distribution networks against operating margin targets.

Timeline and Next Steps

The regulatory filing under Item 5.02 formalizes board appointments without requiring a shareholder vote prior to the standard annual meeting cycle. Duato joins a board overseeing global operations that generated tens of billions of dollars across beverage bottling and convenience food segments.

His formal committee duties begin on December 1, 2026, with the initial cash retainer distribution following at the close of the second quarter in June 2027.

Questions & Answers

Q.

What compensation will Joaquin Duato receive for his board service at PepsiCo?

A.

He will receive an initial grant of 1,000 shares of common stock. Also, he will get a prorated annual equity package in phantom stock units valued at $166,667 and a semi-annual cash retainer payment of $60,000, starting in June 2027.

Q.

What specific expertise does Duato bring to the PepsiCo board from his previous roles?

A.

He brings over three decades of experience in large-scale distribution, consumer health manufacturing, international supply chains, and enterprise-level regulatory risk management. His background includes directing commercial portfolios across consumer health, medical technologies and enterprise software deployment.

Q.

When will Joaquin Duato's formal duties on the audit committee begin?

A.

His formal committee duties are set to begin on December 1, 2026. The first cash retainer payment for his board service is scheduled for distribution in June 2027.

Q.

Why is PepsiCo adding a director with a pharmaceutical background to its board?

A.

PepsiCo is seeking direct access to enterprise-level regulatory risk management as packaged food lines move towards health-focused formulations. This addition is seen as a defensive step for consumer packaged goods boards amidst stricter scrutiny and packaging directives.

Reader pulse

Is this a smart board appointment?

18,101 votes so far

Weekly Briefing

Asia's retail intelligence, in your inbox

Monday, Wednesday and a Friday Weekly Wrap: the retail stories, numbers and moves that mattered across Asia. Nothing else, and you can unsubscribe in one click.

  • Top industry moves and market shifts
  • Weekly data-driven analysis from across Asia
  • Monday, Wednesday and the Friday Weekly Wrap

Read by retail operators, investors and brand teams across Asia.

Protected by a quick human check. No spam, ever. Unsubscribe in one click.

SecureGDPR ready